Literature DB >> 19216621

Telomerase-specific virotherapy for human squamous cell carcinoma.

Toshiyoshi Fujiwara1.   

Abstract

BACKGROUND: Replication-selective tumor-specific viruses present a novel approach for treatment of neoplastic disease. They are designed to induce lysis after propagation within the tumor. Human telomerase is active in over 85% of primary cancers and its activity correlates closely with human telomerase reverse transcriptase (hTERT) expression.
OBJECTIVES: Oncolytic viruses, Telomelysin and TelomeScan, that combine the specificity of hTERT promoter-based expression systems with the lytic efficacy of replicative viruses were developed. The goal was to confirm the efficacy of the viruses for human squamous cell carcinoma. RESULTS/
CONCLUSION: Squamous cell carcinoma of the head and neck (SCCHN) is characterized by locoregional spread, and is clinically accessible, making it an attractive target for intratumoral virotherapy. The viruses replicated efficiently and induced killing in a panel of human cancer cell lines including SCCHN cells in vitro and in vivo. These results illustrate the potential of telomerase-specific oncolytic viruses for treatment of human SCCHN.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19216621     DOI: 10.1517/14712590802715731

Source DB:  PubMed          Journal:  Expert Opin Biol Ther        ISSN: 1471-2598            Impact factor:   4.388


  2 in total

1.  Biological ablation of sentinel lymph node metastasis in submucosally invaded early gastrointestinal cancer.

Authors:  Satoru Kikuchi; Hiroyuki Kishimoto; Hiroshi Tazawa; Yuuri Hashimoto; Shinji Kuroda; Masahiko Nishizaki; Takeshi Nagasaka; Yasuhiro Shirakawa; Shunsuke Kagawa; Yasuo Urata; Robert M Hoffman; Toshiyoshi Fujiwara
Journal:  Mol Ther       Date:  2014-12-19       Impact factor: 11.454

2.  Combination of hTERT knockdown and IFN-gamma treatment inhibited angiogenesis and tumor progression in glioblastoma.

Authors:  Joseph George; Naren L Banik; Swapan K Ray
Journal:  Clin Cancer Res       Date:  2009-11-24       Impact factor: 12.531

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.